News

Entresto was studied in a clinical trial of over 8,000 patients with HFrEF and was shown to reduce the rate of cardiovascular death and hospitalizations related to heart

The study is being conducted in Vienna, Austria, and will examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers. Arsanis chief development officer Rene Russo said:

Bristol-Myers Squibb has invested an undisclosed amount in LSP 5, the latest LSP fund. It is the first investment by the company in a European healthcare fund. A

There were no serious adverse events (SAE) observed in either of the treatment groups, and the incidence of adverse events (AE) was similar between treatment and control groups.

There are an estimated 300,000 total hip replacement surgeries performed in the U.S. each year. Without preventive anticoagulant treatment, the incidence of DVT ranges from 40 to 60

Genvoya is indicated in the European Union to treat adults and adolescents, aged 12 and older with body weight about 35 kg, infected with HIV-1 without any known

The sale is part of the company plan to focus on three main therapy areas and the company said that Entocort is outside its focus area. Entocort had

The hedge fund management company earlier held a stake of 5.7% in the pharmaceutical firm, which develops and markets prescription and non-prescription products. Valeant’s main drug markets include

Allergan’s parent firm will be the parent of the combined new business. The company’s shareholders would receive 11.3 shares of the newly combined firm for each of their